Novo Nordisk Rolls Out Oral Wegovy and Weekly Insulin on Same Day as Supply Chain Hiccups Emerge
Published on 07/10/2026 at 17:54 | Redaktion boerse-global.de
Novo Nordisk unleashed a flurry of product launches on July 10, 2026, putting the oral version of Wegovy on US pharmacy shelves and debuting the world's first once-weekly basal insulin, Awiqli, in India. But the day was not without its blemishes: a CagriSema device study was pulled and a key generics supplier flagged contamination issues. The Danish drugmaker is clearly racing to lock in market share before its rivals close the gap, even as some operational headwinds threaten to slow its momentum.
The oral Wegovy pill, available at more than 70,000 US pharmacies including CVS and Costco, as well as through telemedicine platforms, is priced aggressively to undercut Eli Lilly’s expected offering. The 1.5 mg starter dose costs patients $5 a day, or roughly $149 per month, while the 4 mg and 9 mg versions top out at $199 and $299 respectively until pricing adjustments take effect on April 15 for the middle dose. By contrast, Novo Nordisk’s own injectable Wegovy runs $349 monthly, and Eli Lilly is reportedly planning a $399 ceiling for its oral candidate. Clinical data show the pill delivers roughly 17% weight loss with daily use.
Medicare data released on July 9 underscore the potential — and the persistent gap — in the US obesity drug market. Since the FDA expanded Wegovy’s label in March 2024 to include cardiovascular risk reduction, prescriptions under Medicare Part D surged 598% within six months, climbing from around 367,000 to over 868,000. Yet the USC Schaeffer Center estimates that fewer than 1% of the 3.6 million eligible Medicare beneficiaries have actually filled a script, held back by high copayments and cautious insurance plans. A pilot program dubbed "Medicare GLP-1 Bridge" aims to improve access, though it is already set to expire in 2027.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
In India, where an estimated 101 million people live with diabetes, Novo Nordisk launched Awiqli (insulin icodec) on the same day. The weekly injection cuts the annual jab count from 365 to 52, and the ONWARDS trial series involving over 4,000 adults showed better HbA1c reduction than daily glargine. At roughly 261 rupees per week, the price is positioned for a price-sensitive market. Novo Nordisk CEO Mike Doustdar has pointed to Awiqli as a cornerstone of the company’s push into emerging markets, where diabetes prevalence is climbing fast.
Not all news was positive. A device study for the combination therapy CagriSema — a GLP-1/amylin hybrid that Doustdar expects to win approval by end of 2026 — was withdrawn. Separately, Indian contract manufacturer Dr. Reddy’s halted shipments of generic semaglutide after detecting impurities in its active ingredient. The company slashed its production target for fiscal 2027 from 12 million pens to between 6 million and 7 million, with a resumption not expected until late October or November. Novo Nordisk stressed it is not directly impacted, as Dr. Reddy’s is a generics player, but the episode has injected a note of caution into the broader supply chain for anti-obesity treatments.
On the institutional front, Greenwood Capital Associates added roughly 14,451 shares worth about $531,000 in the first quarter, while Azzad Asset Management boosted its stake by nearly 50%, to 98,290 shares valued at $3.61 million. The analyst consensus remains "Hold" with a $65.56 price target. H.C. Wainwright reiterated a Buy rating on partner Vivani Medical after Novo Nordisk agreed to evaluate its semaglutide implant technology. Amid all the product news, the company also expanded its brand visibility by placing logos on players’ jerseys at Wimbledon 2026.
In Frankfurt, shares of Novo Nordisk traded at €43.02 on Friday, up 0.36% from the prior close of €42.87. The stock has gained nearly 16% over the past 30 days — a recovery from its March 2026 low of €30.25, representing a 42% rebound — but remains 3.70% in the red year-to-date and roughly 30% below its 12-month high of €61.20 from July 2025. The relative strength index stands at 64.7, approaching overbought territory, and the price sits about 9% above its 50-day moving average. The market capitalization stands at €189.31 billion, a far cry from the lofty levels of mid-2025 but a sign that investors are cautiously optimistic about Novo Nordisk’s ability to hold its ground against Eli Lilly and other challengers in the booming obesity and diabetes markets.
Ad
Novo Nordisk Stock: New Analysis - 10 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
